Essential tremor (ET) is one of the most common movement disorders worldwide, characterized by a bilateral, largely symmetric action tremor (postural and kinetic) of the upper limbs at 4-12 Hz, frequently accompanied by tremor of the head, voice, and lower limbs. It is a clinically and genetically heterogeneous syndrome, and the 2018 International Parkinson and Movement Disorder Society consensus redefined it as an isolated tremor syndrome (with an "ET-plus" category for additional soft neurological signs). ET is mechanistically and clinically distinct from the rest tremor of Parkinson disease and from the tremor/ataxia of fragile X-associated tremor/ataxia syndrome (FXTAS). The dominant pathophysiologic model implicates pathological rhythmic oscillation within the olivocerebellar and cerebello-thalamo-cortical circuits, with Purkinje-cell pathology, GABAergic (Purkinje-cell/dentate) dysfunction, and, in a subset, degenerative cerebellar change. Prevalence rises steeply with age (about 1% overall and up to ~5% in those over 65), and a positive family history (often autosomal-dominant-like) is present in a large fraction of patients, although the genetic architecture is predominantly complex/polygenic.
Ask a research question about Essential Tremor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Essential Tremor
creation_date: "2026-07-04T00:00:00Z"
category: Complex
parents:
- Movement Disorder
description: >-
Essential tremor (ET) is one of the most common movement disorders worldwide,
characterized by a bilateral, largely symmetric action tremor (postural and kinetic)
of the upper limbs at 4-12 Hz, frequently accompanied by tremor of the head, voice,
and lower limbs. It is a clinically and genetically heterogeneous syndrome, and the
2018 International Parkinson and Movement Disorder Society consensus redefined it as an
isolated tremor syndrome (with an "ET-plus" category for additional soft neurological
signs). ET is mechanistically and clinically distinct from the rest tremor of Parkinson
disease and from the tremor/ataxia of fragile X-associated tremor/ataxia syndrome
(FXTAS). The dominant pathophysiologic model implicates pathological rhythmic oscillation
within the olivocerebellar and cerebello-thalamo-cortical circuits, with Purkinje-cell
pathology, GABAergic (Purkinje-cell/dentate) dysfunction, and, in a subset, degenerative
cerebellar change. Prevalence rises steeply with age (about 1% overall and up to ~5% in
those over 65), and a positive family history (often autosomal-dominant-like) is present
in a large fraction of patients, although the genetic architecture is predominantly
complex/polygenic.
disease_term:
preferred_term: Essential Tremor
term:
id: MONDO:0003233
label: essential tremor
mappings:
mondo_mappings:
- term:
id: MONDO:0003233
label: essential tremor
mapping_predicate: skos:exactMatch
mapping_source: MONDO
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
Many ET families show an autosomal-dominant-like segregation pattern with incomplete,
age-dependent penetrance and variable expressivity, but most cases arise from complex
polygenic risk rather than single-gene Mendelian inheritance. Linkage studies have been
largely non-reproducible and no single gene explains a substantial fraction of cases.
evidence:
- reference: PMID:24532269
reference_title: "Genetics of essential tremor: meta-analysis and review."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "None of the 3 ETM loci has been confirmed independently with a lod score >2.0 in a single family."
explanation: >-
This meta-analysis/review documents that classical monogenic linkage in ET is not robustly
reproducible, supporting a predominantly complex rather than simple autosomal-dominant model.
prevalence:
- population: Worldwide
measure_type: POINT_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_per_100000: 1000.0
notes: >-
About 1% of the general population overall, rising to roughly 5% in individuals over 65 years.
evidence:
- reference: PMID:41145148
reference_title: "The cerebellar involvement in essential tremor: the connecting roads."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "affecting about 1% of the general population and 5% of those aged over 65 years"
explanation: >-
Establishes ET prevalence with strong age dependence (about 1% overall and about 5% over 65).
mechanistic_hypotheses:
- hypothesis_group_id: canonical_cerebellar_oscillation_gaba_model
hypothesis_label: Canonical Olivocerebellar/Cerebello-Thalamo-Cortical Oscillation and GABAergic-Dysfunction Model
status: CANONICAL
description: >-
The prevailing model holds that ET arises from pathological, synchronized 4-12 Hz oscillation
generated within the olivocerebellar and cerebello-thalamo-cortical circuits. The inferior
olive's intrinsic oscillatory pacemaking, transmitted via climbing fibers, entrains Purkinje
cells to fire synchronously; structural Purkinje-cell pathology (climbing-fiber territory
expansion, axonal torpedoes, dendritic/spine changes, cell loss) and reduced GABAergic
(dentate/Purkinje) inhibitory tone amplify and propagate this rhythmic activity through the
dentate nucleus and thalamus (VIM) to motor cortex, producing action tremor. The GABA
hypothesis is supported by pharmacology (ethanol, benzodiazepines, primidone reduce tremor),
animal models (harmaline/beta-carboline; GABA-A alpha1 loss), and postmortem receptor-binding
studies, though whether reduced GABAergic tone is primary or a consequence of Purkinje-cell
injury remains debated.
evidence:
- reference: PMID:41145148
reference_title: "The cerebellar involvement in essential tremor: the connecting roads."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "demonstrated functional, neurotransmitter-related, and structural abnormalities within the cerebello-thalamo-cortical circuit"
explanation: >-
This review establishes the cerebello-thalamo-cortical circuit (with functional,
neurotransmitter, and structural abnormalities) as the anatomic substrate of ET.
- reference: PMID:35750365
reference_title: "Is essential tremor a disorder of primary GABA dysfunction? Yes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Dysfunction in gamma-aminobutyric acid (GABA) neurotransmission has emerged as a prime suspect for the underlying neurochemical dysfunction in essential tremor (ET)."
explanation: >-
Frames GABAergic dysfunction as the leading neurochemical mechanism, supporting the GABA
arm of the canonical oscillation model.
pathophysiology:
- name: Inferior olivary oscillation and climbing-fiber entrainment
description: >-
Neurons of the inferior olive possess intrinsic oscillatory (pacemaker) properties that,
via climbing-fiber projections, entrain cerebellar Purkinje cells to fire synchronous complex
spikes. Enhanced electrotonic coupling of olivary neurons increases this synchrony. The
harmaline (beta-carboline) rodent model reproduces this mechanism, generating a phenotypically
ET-like action tremor by driving synchronized olivary firing.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: rhythmic synaptic transmission
term:
id: GO:0060024
label: rhythmic synaptic transmission
modifier: INCREASED
downstream:
- target: Purkinje-cell pathology and hypersynchronous firing
causal_link_type: DIRECT
description: >-
Climbing-fiber-driven entrainment imposes synchronous complex-spike firing on Purkinje cells,
the initiating event that couples olivary oscillation to cerebellar cortical output.
evidence:
- reference: PMID:35965995
reference_title: "Cerebello-Thalamo-Cortical Network Dynamics in the Harmaline Rodent Model of Essential Tremor."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Harmaline produces pathological oscillations within the cerebellum, and a tremor that phenotypically resembles ET."
explanation: >-
The harmaline model demonstrates that cerebellar (olivary) oscillation produces an ET-like
tremor, supporting the inferior-olive oscillator as an upstream driver. Model-organism evidence.
- name: Purkinje-cell pathology and hypersynchronous firing
description: >-
Purkinje cells, the sole output neurons of the cerebellar cortex, show multiple structural and
functional abnormalities in the ET cerebellum: expansion of climbing-fiber synaptic territory
into parallel-fiber zones, axonal torpedoes, dendritic/spine changes, and Purkinje-cell loss,
along with transcriptomic dysregulation of RNA-splicing, synapse/ion-transport, and
oxidative-stress/inflammation pathways. These changes render Purkinje-cell output abnormally
synchronous and are proposed to be central to ET pathogenesis, though ET is heterogeneous and
may represent a family of disorders.
cell_types:
- preferred_term: Purkinje cell
term:
id: CL:0000121
label: Purkinje cell
biological_processes:
- preferred_term: chemical synaptic transmission
term:
id: GO:0007268
label: chemical synaptic transmission
modifier: ABNORMAL
downstream:
- target: Cerebellar GABAergic disinhibition
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
description: >-
Purkinje-cell injury and altered inhibitory connectivity contribute to reduced GABAergic
(dentate/Purkinje) inhibitory tone, further destabilizing cerebellar output.
- target: Cerebello-thalamo-cortical oscillatory propagation
causal_link_type: DIRECT
description: >-
Hypersynchronous Purkinje-cell output is transmitted through the deep cerebellar (dentate)
nuclei to the thalamus and motor cortex, propagating the tremor rhythm.
evidence:
- reference: PMID:36242761
reference_title: "Gene Expression Analysis of Laser-Captured Purkinje Cells in the Essential Tremor Cerebellum."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we identified major morphological changes in the ET cerebellum that reflect cellular damage in Purkinje cells (PCs), suggesting that PC damage is central to ET pathogenesis"
explanation: >-
Postmortem morphology and Purkinje-cell-specific transcriptomics establish Purkinje-cell
damage as central to ET, supporting this node.
- reference: PMID:36242761
reference_title: "Gene Expression Analysis of Laser-Captured Purkinje Cells in the Essential Tremor Cerebellum."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Significant heterogeneity among ET combined with dysregulation of multiple cellular processes supports the notion that ET is a family of disorders rather than one disease entity."
explanation: >-
Documents the mechanistic heterogeneity of ET, appropriately hedging the Purkinje-cell model
as one of several converging mechanisms.
- name: Cerebellar GABAergic disinhibition
description: >-
Reduced GABAergic inhibitory tone within the cerebellum contributes to ET. Postmortem studies
report reduced GABA-A and GABA-B receptor binding in the dentate nucleus, and in mouse models
loss of the GABA-A receptor alpha1 subunit from Purkinje cells is sufficient to induce tremor.
It remains debated whether this GABAergic deficit is a primary contributing factor or a
downstream consequence of Purkinje-cell dysfunction/loss. Partial temporary suppression of
tremor by ethanol (via cerebellar alpha6-containing extrasynaptic GABA-A receptors on granule
cells) and by GABAergic drugs supports a functional role for GABAergic signaling.
cell_types:
- preferred_term: GABAergic neuron
term:
id: CL:0000617
label: GABAergic neuron
- preferred_term: cerebellar granule cell
term:
id: CL:0001031
label: cerebellar granule cell
biological_processes:
- preferred_term: gamma-aminobutyric acid signaling pathway
term:
id: GO:0007214
label: gamma-aminobutyric acid signaling pathway
modifier: DECREASED
downstream:
- target: Cerebello-thalamo-cortical oscillatory propagation
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
description: >-
Loss of inhibitory GABAergic tone reduces damping of cerebellar oscillation, facilitating
synchronous rhythmic output that propagates through the tremor circuit.
evidence:
- reference: PMID:35750365
reference_title: "Is essential tremor a disorder of primary GABA dysfunction? Yes."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "It remains to be elucidated whether reduced GABAergic tone is a primary contributing factor to ET pathophysiology, a consequence of altered Purkinje cell function, or even a result of Purkinje cell death."
explanation: >-
Directly states the open question of whether GABAergic deficit is primary or secondary,
justifying PARTIAL support and the hedged causal placement of this node.
- reference: PMID:36830567
reference_title: "GABA-A Alpha 2/3 but Not Alpha 1 Receptor Subunit Ligand Inhibits Harmaline and Pimozide-Induced Tremor in Rats."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "GABA-A receptor is a target for tremorolytic medications"
explanation: >-
Establishes GABA-A receptor signaling as a pharmacological target for tremor suppression,
supporting a mechanistic role for GABAergic tone. Model-organism (rat) evidence.
- name: Cerebello-thalamo-cortical oscillatory propagation
description: >-
Synchronized cerebellar output is relayed through the deep cerebellar (dentate) nuclei to the
ventral intermediate nucleus (VIM) of the thalamus and onward to the motor cortex, producing
coherent oscillatory drive to spinal motor neurons and the clinically observed action tremor.
Aberrant synchronous oscillation across cerebellum, inferior olive, thalamus, and cortex is the
proximate generator of tremor, and the VIM is the principal surgical target for tremor control.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: rhythmic synaptic transmission
term:
id: GO:0060024
label: rhythmic synaptic transmission
modifier: INCREASED
downstream:
- target: Kinetic tremor of the upper limbs
causal_link_type: DIRECT
description: >-
Oscillatory drive to upper-limb motor pathways produces the defining bilateral action
(kinetic and postural) tremor of the arms.
- target: Postural tremor of the upper limbs
causal_link_type: DIRECT
description: >-
The same oscillatory drive produces tremor during sustained antigravity posture.
- target: Head tremor
causal_link_type: DIRECT
description: >-
With disease progression the oscillatory circuit involves axial/cranial musculature,
producing head (and, when laryngeal, voice) tremor.
- target: Voice tremor
causal_link_type: DIRECT
description: >-
Involvement of laryngeal musculature by the tremor circuit produces vocal quavering.
- target: Lower limb tremor
causal_link_type: DIRECT
description: >-
Extension of the oscillatory drive to lower-limb motor pathways produces lower-limb
tremor in later-stage disease.
evidence:
- reference: PMID:35965995
reference_title: "Cerebello-Thalamo-Cortical Network Dynamics in the Harmaline Rodent Model of Essential Tremor."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "resulting in aberrant synchronous oscillatory activity within the thalamo-cortical network leading to tremors"
explanation: >-
Establishes aberrant synchronous thalamo-cortical oscillation as the proximate generator of
tremor. Model-organism evidence complementing human circuit imaging.
- reference: PMID:41145148
reference_title: "The cerebellar involvement in essential tremor: the connecting roads."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "it primarily manifests as postural and kinetic tremors, predominantly in the upper limbs"
explanation: >-
Confirms the upper-limb postural/kinetic action tremor as the principal clinical output of the
circuit dysfunction.
phenotypes:
- category: Neurological
name: Kinetic tremor of the upper limbs
description: >-
Bilateral action (kinetic) tremor of the upper limbs occurring during voluntary movement is the
hallmark feature of ET, often of greater amplitude than the postural component and impairing
writing, drinking, and eating.
phenotype_term:
preferred_term: Kinetic tremor
term:
id: HP:0030186
label: Kinetic tremor
clinical_course: PROGRESSIVE
evidence:
- reference: PMID:36242761
reference_title: "Gene Expression Analysis of Laser-Captured Purkinje Cells in the Essential Tremor Cerebellum."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Essential tremor (ET) is a common, progressive neurological disease characterized by an 8-12-Hz kinetic tremor."
explanation: Establishes kinetic tremor as the defining, progressive feature of ET.
- category: Neurological
name: Postural tremor of the upper limbs
description: >-
Bilateral tremor of the upper limbs while maintaining a posture against gravity (e.g., arms
outstretched), present in essentially all ET patients.
phenotype_term:
preferred_term: Postural tremor
term:
id: HP:0002174
label: Postural tremor
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "bilateral upper limb postural or kinetic"
explanation: >-
Defines ET as a bilateral upper-limb postural or kinetic tremor syndrome, supporting postural
tremor as a core phenotype.
- category: Neurological
name: Head tremor
description: >-
Tremor of the head (titubation), typically developing after years of upper-limb involvement and
more common in women.
phenotype_term:
preferred_term: Head tremor
term:
id: HP:0002346
label: Head tremor
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "tremor of head, voice, or lower limbs"
explanation: >-
Documents head (and voice and lower-limb) tremor as recognized extensions of the ET syndrome.
- category: Neurological
name: Voice tremor
description: >-
Laryngeal tremor causing vocal quavering (a tremulous, oscillating voice), developing with
disease progression.
phenotype_term:
preferred_term: Voice tremor
term:
id: HP:0001618
label: Dysphonia
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "tremor of head, voice, or lower limbs"
explanation: >-
Voice tremor is a recognized component of the ET syndrome; mapped to the closest HPO term
(Dysphonia) with a more specific preferred_term.
- category: Neurological
name: Lower limb tremor
description: >-
Tremor of the lower limbs, an anatomic extension of the action tremor that may appear after
years of disease progression from the upper limbs.
phenotype_term:
preferred_term: Lower limb tremor
term:
id: HP:0001337
label: Tremor
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "tremor of head, voice, or lower limbs"
explanation: >-
Lower-limb tremor is a recognized part of the ET syndrome; mapped to the generic Tremor HPO
term with a more specific preferred_term.
- category: Neurological
name: Cognitive impairment
description: >-
A subset of ET patients develop mild cognitive impairment (and elevated dementia risk),
part of the recognized non-motor spectrum of ET; more prominent in the ET-plus category.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Cognitive impairment
term:
id: HP:0100543
label: Cognitive impairment
evidence:
- reference: PMID:40867132
reference_title: "Tremor: Clinical Frameworks, Network Dysfunction and Therapeutics."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "introduced new diagnostic categories, such as essential tremor plus"
explanation: >-
The ET-plus category (which encompasses mild cognitive complaints among soft signs) is
documented; PARTIAL because the snippet supports the category rather than a precise frequency.
genetic:
- name: LINGO1
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: LINGO1
term:
id: hgnc:21205
label: LINGO1
notes: >-
First replicated ET GWAS susceptibility signal (rs9652490). Confers modest risk in a complex
polygenic architecture rather than acting as a Mendelian cause.
evidence:
- reference: PMID:24532269
reference_title: "Genetics of essential tremor: meta-analysis and review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our meta-analysis confirmed the association of rs9652490 in LINGO1 with ET."
explanation: >-
Confirms the LINGO1 rs9652490 association with ET as a replicated susceptibility signal.
- name: FUS
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: FUS
term:
id: hgnc:4010
label: FUS
notes: >-
A rare FUS mutation was identified in a single ET family by exome sequencing; replication in
other families has been limited, so FUS represents a rare familial contribution rather than a
common risk factor.
evidence:
- reference: PMID:24532269
reference_title: "Genetics of essential tremor: meta-analysis and review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A mutation in the FUS gene (fused in sarcoma) was found in one ET family by exome sequencing."
explanation: >-
Documents the rare FUS mutation in a single ET family, appropriately hedged as a rare familial
contribution.
- name: SLC1A2
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: SLC1A2
term:
id: hgnc:10940
label: SLC1A2
notes: >-
Encodes the major glial glutamate transporter EAAT2; a GWAS reported association with ET,
implicating glutamatergic handling in ET susceptibility.
evidence:
- reference: PMID:24532269
reference_title: "Genetics of essential tremor: meta-analysis and review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the SLC1A2 gene (solute carrier family 1 member 2) and ET"
explanation: >-
Documents the GWAS association of SLC1A2 with ET.
- name: CA3
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: CA3
term:
id: hgnc:1374
label: CA3
notes: >-
Putative causal gene highlighted at a GWAS meta-analysis risk locus. CA3 (carbonic anhydrase 3)
is notable because carbonic anhydrase inhibitors can reduce tremor. Association is a polygenic
susceptibility signal rather than a Mendelian cause.
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we highlight seven putative causal genes at these loci, including CA3 and CPLX1"
explanation: >-
Identifies CA3 as a putative causal gene from a 16,480-case GWAS meta-analysis,
supporting the polygenic architecture of ET.
- name: CPLX1
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: CPLX1
term:
id: hgnc:2309
label: CPLX1
notes: >-
Putative causal gene highlighted at a GWAS meta-analysis risk locus. CPLX1 (complexin 1)
regulates SNARE-mediated neurotransmitter release. Association is a polygenic susceptibility
signal rather than a Mendelian cause.
evidence:
- reference: PMID:38671141
reference_title: "GWAS meta-analysis reveals key risk loci in essential tremor pathogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we highlight seven putative causal genes at these loci, including CA3 and CPLX1"
explanation: >-
Identifies CPLX1 as a putative causal gene from a 16,480-case GWAS meta-analysis,
supporting the polygenic architecture of ET.
environmental:
- name: Harmane / beta-carboline exposure
notes: >-
Harmane (a beta-carboline) has been epidemiologically associated with ET, and the related
compound harmaline is the classic tremorigenic agent used to model ET in rodents, implicating
beta-carboline exposure as a candidate environmental contributor.
evidence:
- reference: PMID:35965995
reference_title: "Cerebello-Thalamo-Cortical Network Dynamics in the Harmaline Rodent Model of Essential Tremor."
supports: PARTIAL
evidence_source: MODEL_ORGANISM
snippet: "Harmaline produces pathological oscillations within the cerebellum, and a tremor that phenotypically resembles ET."
explanation: >-
The tremorigenic action of the beta-carboline harmaline supports the biological plausibility
of beta-carboline exposure as an ET-relevant environmental factor. Model-organism evidence.
- name: Aging
notes: >-
Increasing age is the strongest non-genetic risk factor; prevalence rises from about 1% overall
to roughly 5% in individuals over 65 years.
evidence:
- reference: PMID:41145148
reference_title: "The cerebellar involvement in essential tremor: the connecting roads."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "affecting about 1% of the general population and 5% of those aged over 65 years"
explanation: >-
Documents the strong age dependence of ET prevalence, supporting aging as the principal
non-genetic risk factor.
treatments:
- name: Propranolol
description: >-
Nonselective beta-adrenergic blocker; a guideline-supported first-line oral therapy for ET and
the only FDA-approved medication, reducing tremor amplitude in responders. Contraindicated in
asthma/COPD and limited by bradycardia, hypotension, and fatigue.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: propranolol
term:
id: CHEBI:8499
label: propranolol
evidence:
- reference: PMID:39498461
reference_title: "Treatment for essential tremor: a systematic review and Bayesian Model-based Network Meta-analysis of RCTs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our study results indicate that CX-8998, propranolol, and atenolol demonstrate relative efficacy and safety in treating ET."
explanation: >-
A Bayesian network meta-analysis of RCTs concludes propranolol demonstrates relative efficacy
and safety in treating ET, supporting its first-line role.
- name: Primidone
description: >-
Barbiturate-related antiseizure drug that enhances GABAergic inhibition (via its phenobarbital
metabolite and related effects); a guideline-supported first-line oral therapy for ET, limited
by sedation, dizziness, nausea, and ataxia.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: primidone
term:
id: CHEBI:8412
label: primidone
evidence:
- reference: PMID:35927430
reference_title: "Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "many patients are responsive to two drugs: propranolol and primidone"
explanation: >-
Confirms propranolol and primidone as the two standard drugs to which many ET patients
respond. The cited paper reports cell-based transcriptomics (IN_VITRO).
- name: Topiramate
description: >-
Antiseizure drug with multimodal action (including enhancement of GABAergic tone); a
second-line, off-label option for ET with variable benefit, limited by cognitive slowing,
paresthesia, and weight loss.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: topiramate
term:
id: CHEBI:63631
label: topiramate
evidence:
- reference: PMID:18382182
reference_title: "Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To evaluate topiramate in adults with essential tremor"
explanation: >-
Double-blind, placebo-controlled crossover trials of topiramate in essential tremor found
significantly lower total tremor scores with topiramate versus placebo, supporting topiramate
as an efficacious (second-line) pharmacotherapy for ET.
- name: Gabapentin
description: >-
Modulator of the alpha2-delta calcium-channel subunit; a second-line, off-label option for ET
with modest and inconsistent benefit, limited by somnolence, dizziness, and imbalance.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: gabapentin
term:
id: CHEBI:42797
label: gabapentin
evidence:
- reference: PMID:22886006
reference_title: "Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "zonisamide, gabapentin, alprazolam,"
explanation: >-
This evidence-based systematic review and guideline lists gabapentin among the agents
recommended as second-line treatment for essential tremor.
- name: Deep Brain Stimulation of the VIM Thalamus
description: >-
High-frequency stimulation of the ventral intermediate (VIM) nucleus of the thalamus modulates
the cerebello-thalamo-cortical circuit and is an established neurosurgical therapy for
medication-refractory ET, ranked first for relative efficacy in network meta-analysis.
therapeutic_modality: DEVICE
treatment_term:
preferred_term: deep brain stimulation
term:
id: MAXO:0000943
label: deep brain stimulation
evidence:
- reference: PMID:39498461
reference_title: "Treatment for essential tremor: a systematic review and Bayesian Model-based Network Meta-analysis of RCTs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "DBS is effective for medication-resistant ET and ranks first in relative efficacy"
explanation: >-
The network meta-analysis concludes DBS is effective for medication-resistant ET and ranks
first in relative efficacy, supporting its role for medication-refractory ET.
- name: MR-Guided Focused Ultrasound Thalamotomy
description: >-
Incisionless MRI-guided focused ultrasound (MRgFUS) thermal lesioning of the VIM thalamus, a
non-invasive surgical alternative to DBS for medication-refractory ET; adverse effects include
gait instability and paresthesia.
therapeutic_modality: SURGERY
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
evidence:
- reference: PMID:39498461
reference_title: "Treatment for essential tremor: a systematic review and Bayesian Model-based Network Meta-analysis of RCTs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "magnetic resonance guided focus ultrasound (MR-FUS) (0.624)"
explanation: >-
The network meta-analysis ranks MR-guided focused ultrasound among effective interventions
for ET, supporting MRgFUS thalamotomy as an established option.
Essential tremor (ET) is the most common neurological movement disorder worldwide, characterized by bilateral, rhythmic, involuntary action tremor primarily affecting the upper limbs at frequencies of 4–12 Hz (ortegarobles2025tremorclinicalframeworks pages 13-15, ortegarobles2025tremorclinicalframeworks pages 2-4). It manifests predominantly as postural and kinetic tremor, impairing activities of daily living including writing, drinking, and eating (buyukserbetci2025clinicalandgenetic pages 1-2). Unlike resting tremor seen in Parkinson's disease (PD), ET is not typically observed at rest. The 2018 consensus criteria of the International Parkinson and Movement Disorder Society (IPMDS) redefined ET as a heterogeneous syndrome with variable clinical features and diverse underlying mechanisms, moving beyond the previous classification of it as purely idiopathic or familial (ortegarobles2025tremorclinicalframeworks pages 2-4).
ET is classified as a complex, multifactorial neurological disorder with both genetic and environmental contributions (buyukserbetci2025clinicalandgenetic pages 1-2, kuhlenbaumer2014geneticsofessential pages 1-3).
ET develops through multifactorial genetic and environmental interactions rather than simple Mendelian inheritance (buyukserbetci2025clinicalandgenetic pages 1-2). Twin study concordance rates of 69–93% in monozygotic twins and 27–29% in dizygotic twins confirm the strong genetic component alongside environmental contributions (buyukserbetci2025clinicalandgenetic pages 1-2).
Family history is present in 30–70% of ET patients, with first-degree relatives showing a 4.7-fold increased risk (ortegarobles2025tremorclinicalframeworks pages 13-15, kuhlenbaumer2014geneticsofessential pages 1-3). GWAS studies have identified numerous susceptibility loci:
Skuladottir et al. (2024): A landmark GWAS meta-analysis comprising 16,480 ET cases and 1,936,173 controls identified 12 sequence variants at 11 loci, with 8 being novel, explaining ~4.4% of genetic variance. Seven putative causal genes were highlighted, including CA3 (Carbonic Anhydrase III) and CPLX1 (Complexin-1). Gene-set enrichment identified associations with dopaminergic and GABAergic neurons, and genetic correlation with PD (rg = 0.28) and depression (rg = 0.15) (skuladottir2024gwasmetaanalysisreveals pages 1-2, skuladottir2024gwasmetaanalysisreveals pages 2-4).
Ogonowski et al. (2025): A genome-wide meta-analysis of 20,268 ET cases and 723,761 controls identified 50 independent loci (47 novel). SNP-based heritability was estimated at 24% (18.5% on the liability scale). Key implicated genes include BACE2, CACNA1A, PPARGC1A, and PPM1J. Spatial transcriptomics highlighted enrichment in hippocampal and cortical excitatory neurons, astrocytes, and microglia (ogonowski2025genomewidemetaanalysisidentifies pages 3-5, ogonowski2025genomewidemetaanalysisidentifies pages 7-9, ogonowski2025genomewidemetaanalysisidentifies pages 1-3).
Previously established candidate genes include LINGO1 (first ET GWAS signal, rs9652490; p = 1.2 × 10⁻²⁹), FUS (stop-gain variant in a Franco-Canadian family), TENM4 (missense mutations affecting axon guidance and myelination), and STK32B (rs10937625; OR = 1.50 in Chinese populations) (kuhlenbaumer2014geneticsofessential pages 1-3, kuhlenbaumer2014geneticsofessential pages 4-6, cao2023associationanalysisof pages 7-8).
Harmane (a β-carboline) exposure has been identified as a potential environmental trigger, and the harmaline model demonstrates the tremorigenic properties of this compound class (kosmowska2023gabaaalpha23 pages 2-3). Age is the strongest non-genetic risk factor, with prevalence increasing dramatically after 65 years (ortegarobles2025tremorclinicalframeworks pages 13-15). Potential roles for Toxoplasma gondii and Toxocara spp. infections as etiologic factors have been explored in preliminary studies.
Approximately 50–75% of ET patients report temporary tremor suppression from alcohol consumption (kuhlenbaumer2014geneticsofessential pages 1-3). This response has been mechanistically linked to modulation of extra-synaptic α6β3δ GABAA receptors on cerebellar granule cells (handforth2023searchfornovel pages 1-2, kuo2023gabaareceptorsubtype pages 1-2).
Recent gut microbiome research demonstrates a novel gene-environment interaction axis: ET patients show reduced GABA-producing gut bacteria and lower fecal GABA concentrations, and fecal microbiota transplantation from ET patients into mice extends tremor duration (zhong2023supplementationwithhighgabaproducing pages 7-14, zhong2023supplementationwithhighgabaproducing pages 1-2). This suggests that gut microbial GABA production, transmitted via the enteric nervous system–vagus nerve–brain axis, interacts with genetic predisposition to influence disease expression (zhong2023supplementationwithhighgabaproducing pages 14-17).
The following table summarizes the key genetic loci and candidate genes associated with ET:
| Gene Symbol | Chromosome/Locus | Study/Year | Evidence Type | Key Finding | PMID where available |
|---|---|---|---|---|---|
| LINGO1 | 15q24.3 | deCODE GWAS; summarized in Kuhlenbäumer et al. / 2022 review | GWAS | First ET GWAS signal; rs9652490 reached genome-wide significance in combined analysis (reported p = 1.2 × 10⁻²⁹); LINGO1 remains one of the strongest replicated susceptibility signals in ET genetics (kuhlenbaumer2014geneticsofessential pages 4-6, ortegarobles2025tremorclinicalframeworks pages 13-15) | 16650084, 16809426 (OpenTargets Search: Essential Tremor) |
| FUS | 16p11.2 | Exome sequencing family study; summarized in Kuhlenbäumer et al. / 2022 review | Exome / familial | Stop-gain variant c.868C>T (p.Gln290*) segregated with ET in a Franco-Canadian family; follow-up studies found limited additional mutations, so evidence supports rare familial contribution rather than common risk (kuhlenbaumer2014geneticsofessential pages 4-6, buyukserbetci2025clinicalandgenetic pages 1-2) | 19861302, 22863194 (OpenTargets Search: Essential Tremor) |
| TENM4 | 11q14-q21 | Familial sequencing / prior linkage-supported candidate; OpenTargets | Familial / candidate gene | Missense mutations reported in familial ET; gene implicated in axon guidance and central myelination; currently among the strongest disease-target associations in OpenTargets for ET (buyukserbetci2025clinicalandgenetic pages 1-2, cao2023associationanalysisof pages 7-8, OpenTargets Search: Essential Tremor) | 26188006 (OpenTargets Search: Essential Tremor) |
| STK32B | 4p16.2 | Common variant association in Chinese cohort / 2023; susceptibility locus in later GWAS meta-analyses | GWAS / replication | rs10937625 in/near STK32B associated with increased ET risk in eastern Chinese cohort (OR 1.50, 95% CI 1.17–1.93); STK32B also prioritized as a susceptibility locus in later meta-analysis (cao2023associationanalysisof pages 7-8, ogonowski2025genomewidemetaanalysisidentifies pages 9-11) | Not provided in context |
| CA3 | 8q21.2 | Skuladottir et al. / 2024 | GWAS meta-analysis | Skuladottir 2024 meta-analysis (16,480 cases, 1,936,173 controls) identified 12 sequence variants at 11 loci and highlighted CA3 as a putative causal gene; protective lead variant correlated with lower CA3 expression/plasma carbonic anhydrase, nominating carbonic anhydrase biology as therapeutic target (skuladottir2024gwasmetaanalysisreveals pages 1-2, skuladottir2024gwasmetaanalysisreveals pages 2-4) | 38671141 |
| CPLX1 | 4p16.3 | Skuladottir et al. / 2024 | GWAS meta-analysis | Intronic risk variant implicated CPLX1, a regulator of neurotransmitter release; top cis-eQTL signal in blood strengthened candidacy as ET gene in Skuladottir 2024 (skuladottir2024gwasmetaanalysisreveals pages 1-2, skuladottir2024gwasmetaanalysisreveals pages 4-4) | 38671141 |
| BACE2 | 21q22.3 | Single-cell cerebellar eQTL / 2024; Ogonowski / 2025 | Single-cell eQTL integrated with GWAS / GWAS meta-analysis | ET-associated variants at the BACE2 locus were causally linked to BACE2 downregulation in cerebellar immature oligodendrocytes, suggesting oligodendrocyte vulnerability/demyelination; BACE2 also emerged as a causal gene in the 2025 meta-analysis (castonguay2024asinglecelleqtl pages 1-5, ogonowski2025genomewidemetaanalysisidentifies pages 9-11) | 39024449 (OpenTargets Search: Essential Tremor) |
| CACNA1A | 19p13.13 | Ogonowski et al. / 2025 | GWAS meta-analysis | Prioritized among significant loci in 2025 meta-analysis; biologically plausible ET gene because it encodes the P/Q-type calcium channel, linking ET risk to neuronal calcium homeostasis and cerebellar signaling (ogonowski2025genomewidemetaanalysisidentifies pages 7-9, ogonowski2025genomewidemetaanalysisidentifies pages 9-11) | Not provided in context |
| EHBP1 | 2p15 | Ogonowski et al. / 2025; Skuladottir et al. / 2024 | GWAS / replicated locus | Replicated previously reported ET locus in 2025 meta-analysis; nearby variation also raised OTX1 as a candidate effector in 2024 GWAS interpretation (ogonowski2025genomewidemetaanalysisidentifies pages 7-9, skuladottir2024gwasmetaanalysisreveals pages 4-4, OpenTargets Search: Essential Tremor) | 38671141 (OpenTargets Search: Essential Tremor) |
| SLC1A2 | 11p13-p12 | Prior GWAS; summarized in Kuhlenbäumer / 2022 review | GWAS | Encodes major glial glutamate transporter EAAT2; achieved genome-wide significance in earlier ET GWAS work and supports glutamatergic involvement in ET pathophysiology (kuhlenbaumer2014geneticsofessential pages 4-6, zeng2024associationanalysisof pages 8-9) | Not provided in context |
| CALN1 | 7q11.23 | OpenTargets / linked to recent ET genetics | GWAS-linked target prioritization | CALN1 is listed among current ET-associated targets in OpenTargets with evidence derived from recent ET genetic studies, supporting calcium-signaling-related mechanisms (OpenTargets Search: Essential Tremor) | 39024449 (OpenTargets Search: Essential Tremor) |
| PPM1J | 1q32.1 | Ogonowski et al. / 2025; OpenTargets | GWAS meta-analysis | Identified among key genes/loci in 2025 GWAS meta-analysis; encodes Mg²⁺/Mn²⁺-dependent phosphatase and contributes to expanded common-variant architecture of ET (ogonowski2025genomewidemetaanalysisidentifies pages 7-9, OpenTargets Search: Essential Tremor) | 39024449 (OpenTargets Search: Essential Tremor) |
| PIK3R1 | 5q13.1 | OpenTargets / recent ET genetic studies | GWAS-linked target prioritization | Appears among ET-associated targets in OpenTargets based on recent human genetic evidence, suggesting PI3K signaling may contribute to ET susceptibility (OpenTargets Search: Essential Tremor) | 38671141, 39024449 (OpenTargets Search: Essential Tremor) |
| NOTCH2NLC | 1q21.2 | Repeat-expansion disorder overlap studies; OpenTargets | Repeat expansion / syndromic overlap | Associated mainly with hereditary essential tremor subtype/NIID-spectrum overlap rather than typical complex ET; illustrates diagnostic overlap between clinically defined ET and repeat-expansion disorders (OpenTargets Search: Essential Tremor, buyukserbetci2025clinicalandgenetic pages 1-2) | 32333675 (OpenTargets Search: Essential Tremor) |
| PPARGC1A | 4p15.1 | Ogonowski et al. / 2025 | GWAS meta-analysis | Prioritized in 2025 meta-analysis; implicates mitochondrial biogenesis/energy metabolism (PGC-1α biology) in ET genetic risk architecture (ogonowski2025genomewidemetaanalysisidentifies pages 7-9) | Not provided in context |
| ET GWAS summary | Multiple loci | Skuladottir 2024 | GWAS meta-analysis | 16,480 ET cases and 1,936,173 controls; 12 sequence variants at 11 loci (8 novel); ~4.4% of genetic variance explained; putative causal genes included CA3 and CPLX1; enrichment in dopaminergic and GABAergic neurons; positive genetic correlation with Parkinson's disease (rg = 0.28) (skuladottir2024gwasmetaanalysisreveals pages 1-2, skuladottir2024gwasmetaanalysisreveals pages 2-4) | 38671141 |
| ET GWAS summary | Multiple loci | Ogonowski 2025 | GWAS meta-analysis (preprint) | 20,268 ET cases and 723,761 controls; 50 independent genome-wide significant loci, 47 novel; SNP-based heritability 24% (18.5% liability scale); implicated BACE2, CACNA1A, PPARGC1A, PPM1J and cerebellar/ventral diencephalic morphometry (ogonowski2025genomewidemetaanalysisidentifies pages 3-5, ogonowski2025genomewidemetaanalysisidentifies pages 7-9, ogonowski2025genomewidemetaanalysisidentifies pages 1-3) | Not yet available in context |
| OpenTargets ET disease node | MONDO_0003233 | OpenTargets (current database snapshot) | Integrated genetics / target prioritization | ET is mapped to MONDO_0003233; top associated targets include TENM4, FUS, NOTCH2NLC, BACE2, DRD3, SCN4A, CALN1, PPM1J, PIK3R1, EHBP1, and SLC24A2 (OpenTargets Search: Essential Tremor) | Database context only |
Table: This table summarizes major ET-associated genes across GWAS, familial/exome, and repeat-expansion studies, with emphasis on the 2024 and 2025 large-scale genetic analyses. It is useful for linking named candidate genes to their study context, evidence type, and current level of support.
ET-plus represents patients exhibiting the core ET phenotype plus additional soft neurological signs including impaired tandem gait, questionable dystonic posturing, mild cognitive complaints, or rest tremor not meeting criteria for PD (ortegarobles2025tremorclinicalframeworks pages 15-16, erro2023diagnosisversusclassification pages 2-3, ortegarobles2025tremorclinicalframeworks pages 10-12). ET-plus patients tend to be older at onset, have more severe tremor, and show greater head/voice involvement (ortegarobles2025tremorclinicalframeworks pages 15-16).
Greater tremor severity (measured by TETRAS Performance Item 4) is positively correlated with activities of daily living impairment (Pearson r = 0.761) and negatively associated with quality of life (EQ-5D-5L: r = −0.410; QUEST: r = 0.457) (ortegarobles2025tremorclinicalframeworks pages 12-13). Up to 92.8% of affected individuals in population-based studies are unaware of their diagnosis, indicating substantial under-recognition (ortegarobles2025tremorclinicalframeworks pages 13-15).
ET is genetically complex, with most cases arising from polygenic risk rather than monogenic mutations (kuhlenbaumer2014geneticsofessential pages 1-3). Key genetic findings include:
Common variants explain approximately 24% of phenotypic variance in ET (h² = 0.24, SE = 0.02), corresponding to 18.5% on the liability scale at 5% population prevalence (ogonowski2025genomewidemetaanalysisidentifies pages 3-5, ogonowski2025genomewidemetaanalysisidentifies pages 1-3).
No well-established epigenetic biomarkers are currently validated for ET. However, transcriptomic studies suggest RNA splicing dysregulation in Purkinje cells, with differentially expressed spliceosome complex components (RBM25, PRPF38B, PNN, SREK1) identified in laser-captured ET Purkinje cells (martuscello2023geneexpressionanalysis pages 9-11).
Harmane (1-methyl-9H-pyrido[3,4-b]indole), a β-carboline found in cooked meats and cigarette smoke, has been epidemiologically associated with ET (kosmowska2023gabaaalpha23 pages 2-3). The harmaline model directly demonstrates the tremorigenic potential of β-carboline compounds.
Alcohol consumption (ethanol at non-intoxicating doses) temporarily suppresses tremor in 50–75% of patients, acting via cerebellar α6β3δ extra-synaptic GABAA receptors (kuhlenbaumer2014geneticsofessential pages 1-3, handforth2023searchfornovel pages 1-2). Dietary GABA intake and gut microbiome composition may modulate disease through the gut-brain axis (zhong2023supplementationwithhighgabaproducing pages 7-14, zhong2023supplementationwithhighgabaproducing pages 14-17).
ET patients demonstrate reduced gut microbial GABA-producing capacity and lower fecal GABA concentration compared to healthy controls (zhong2023supplementationwithhighgabaproducing pages 7-14, zhong2023supplementationwithhighgabaproducing pages 1-2). Supplementation with high-GABA-producing Lactobacillus plantarum L5 (producing 262 mg/L GABA) ameliorated tremor in mouse models by reshaping gut microbial composition, increasing cerebellar GABA concentrations, and diminishing CNS inflammation (zhong2023supplementationwithhighgabaproducing pages 5-7, zhong2023supplementationwithhighgabaproducing pages 1-2).
ET pathophysiology centers on dysfunction within the cerebello-thalamo-cortical circuit, with multiple complementary mechanisms proposed (ortegarobles2025tremorclinicalframeworks pages 13-15, ortegarobles2025tremorclinicalframeworks pages 6-8):
Purkinje cells (CL:0000121), the sole output neurons of the cerebellar cortex, exhibit multiple structural and functional abnormalities in ET (camargo2025thecerebellarinvolvement pages 2-4, camargo2025thecerebellarinvolvement pages 1-2, martuscello2023geneexpressionanalysis pages 12-14): - Expansion of climbing fiber synaptic territory into parallel fiber zones, correlating with tremor severity - Purkinje cell loss and axonal torpedo formation - Dendritic spine loss and morphological changes - Reduced GluRδ2 protein expression leading to deficient synaptic pruning of climbing fibers - Gene expression dysregulation including RNA splicing components, calcium signaling genes (CACNA1G, ITPR1), and inflammatory markers (IL-2, IL-6) (martuscello2023geneexpressionanalysis pages 9-11, martuscello2023geneexpressionanalysis pages 6-7)
Postmortem analysis reveals reduced GABA-A and GABA-B receptor binding in the dentate nucleus of ET patients (camargo2025thecerebellarinvolvement pages 2-4). GABA-A receptor α1 subunit loss from Purkinje cells is sufficient to induce tremor in mouse models (kosmowska2023gabaaalpha23 pages 16-17, pan2026circuitrydynamicsof pages 32-34). However, the primary source of GABAergic dysfunction is debated—it may be a consequence rather than a cause of Purkinje cell pathology (gironell2022isessentialtremor pages 1-2).
The inferior olive's intrinsic oscillatory properties influence Purkinje cell pacemaking through climbing fiber connections (camargo2025thecerebellarinvolvement pages 2-4, camargo2025thecerebellarinvolvement pages 1-2). Harmaline directly enhances coupling of inferior olivary neurons, which then entrain Purkinje cells to fire synchronously (kuo2023gabaareceptorsubtype pages 1-2, woodward2022cerebellothalamocorticalnetworkdynamics pages 1-2).
A groundbreaking single-cell eQTL atlas of the human cerebellum (>1 million cells from 109 individuals) revealed that ET-associated genetic variants at the BACE2 locus are causally linked to BACE2 downregulation specifically in cerebellar oligodendrocytes (castonguay2024asinglecelleqtl pages 1-5). A genetically vulnerable subpopulation of BACE2-expressing immature oligodendrocytes was identified, displaying altered mRNA related to axonal and synaptic homeostasis suggestive of demyelination (castonguay2024asinglecelleqtl pages 1-5, castonguay2024asinglecelleqtl pages 45-47). Dysfunctional interactions between Golgi cells, Purkinje layer interneurons, and oligodendrocytes were also observed in ET tissue (castonguay2024asinglecelleqtl pages 1-5).
Key pathways implicated include: - Calcium signaling (GO:0005509, GO:0019722) — including CACNA1G, CACNA1A, CaMKK2 (martuscello2023geneexpressionanalysis pages 9-11, castonguay2022transcriptomiceffectsof pages 3-4) - Rho GTPase signaling (GO:0007264) (skuladottir2024gwasmetaanalysisreveals pages 1-2) - Axon guidance (GO:0007411) — Semaphorin interactions, RUNX1-mediated growth cone guidance (castonguay2022transcriptomiceffectsof pages 3-4) - Endosomal sorting (castonguay2022transcriptomiceffectsof pages 1-2) - GABAergic neurotransmission (GO:0007214) (ortegarobles2025tremorclinicalframeworks pages 13-15, camargo2025thecerebellarinvolvement pages 2-4) - Glutamatergic signaling via GluRδ2 (ortegarobles2025tremorclinicalframeworks pages 13-15)
ET typically presents bilaterally but may be asymmetric; kinetic tremor is often more prominent on the dominant hand side (ortegarobles2025tremorclinicalframeworks pages 15-16, ortegarobles2025tremorclinicalframeworks pages 10-12).
Age of onset follows a bimodal distribution with peaks in early adulthood (~20 years) and late life (~60 years), with an additional smaller peak near childhood (kuhlenbaumer2014geneticsofessential pages 1-3). Onset is insidious and chronic, with gradual worsening over decades (ortegarobles2025tremorclinicalframeworks pages 15-16, ortegarobles2025tremorclinicalframeworks pages 13-15).
Tremor amplitude progressively increases over time, and anatomical spread extends from upper limbs to head, voice, jaw, and legs after years of disease progression (ortegarobles2025tremorclinicalframeworks pages 15-16, ortegarobles2025tremorclinicalframeworks pages 13-15). The condition is chronic and lifelong with no spontaneous remission. Disease duration correlates with greater functional impairment and broader body region involvement.
A prospective longitudinal study of 193 ET patients (mean age 78.1 years, mean follow-up 4.1 years) found that 3.6% converted from ET to ETPD, with incidence of 882.8 per 100,000 person-years — 2 to 6.5 times higher than the general population rate (louis2023conversionrateof pages 4-5, louis2023conversionrateof pages 1-2). A Spanish population-based cohort reported 3.0% ET-to-PD conversion over median 3.3-year follow-up, with adjusted relative risk of 4.27 (louis2025theassociationbetween pages 4-5). Lifetime risk estimates suggest 8.5% of men and 5.6% of women with ET will develop PD, compared to 2.0% and 1.3% respectively in those without ET (louis2025theassociationbetween pages 4-5).
ET is genetically complex (multifactorial/polygenic) with occasional families showing autosomal dominant-like segregation patterns (kuhlenbaumer2014geneticsofessential pages 1-3, buyukserbetci2025clinicalandgenetic pages 1-2). Penetrance is incomplete and variable; expressivity is highly variable across individuals and families.
ET affects men and women approximately equally, though some data suggest slightly higher prevalence in men, and ET-to-PD conversion rates are higher in men (6.9%) than women (1.65%) (ortegarobles2025tremorclinicalframeworks pages 13-15, louis2023conversionrateof pages 4-5).
ET is found in all ethnic and geographic populations studied. Genetic risk factors may differ across populations — for example, rs10937625 in STK32B is associated with ET risk specifically in eastern Chinese populations (cao2023associationanalysisof pages 7-8).
The 2018 IPMDS consensus criteria define ET as isolated bilateral upper limb action tremor of at least 3 years' duration without additional neurological signs (dystonia, ataxia, parkinsonism) (ortegarobles2025tremorclinicalframeworks pages 15-16, ortegarobles2025tremorclinicalframeworks pages 2-4). Diagnosis is primarily clinical, employing a two-axis system: Axis 1 (syndromic diagnosis) and Axis 2 (etiology) (ortegarobles2025tremorclinicalframeworks pages 2-4).
Key conditions to differentiate from ET include enhanced physiological tremor, parkinsonian tremor (rest > action), dystonic tremor, cerebellar tremor, orthostatic tremor, and functional tremor (ortegarobles2025tremorclinicalframeworks pages 10-12). Distinction from PD relies on differentiating postural vs. re-emergent tremor patterns, finger pronation-supination movements, and associated neurological signs (ortegarobles2025tremorclinicalframeworks pages 15-16). DAT-SPECT imaging can help distinguish ET from PD, and neuromelanin-sensitive MRI has shown promise (ortegarobles2025tremorclinicalframeworks pages 10-12).
Genetic testing for ET is not routinely recommended as no single causal gene accounts for a substantial proportion of cases (kuhlenbaumer2014geneticsofessential pages 1-3). Short tandem repeat (STR) expansion testing may be considered to rule out spinocerebellar ataxias and NIID in cases with overlapping phenotypes; among 515 familial ET probands, 3.7% carried intermediate or pathogenic STR expansions in ataxia-associated genes (cao2023associationanalysisof pages 7-8).
ET is not directly life-threatening, and most patients have near-normal life expectancy. However, ET serves as a significant risk factor for PD (4–5-fold increased risk) (louis2025theassociationbetween pages 4-5, louis2023conversionrateof pages 1-2), and mild cognitive impairment and dementia risks are elevated in ET populations.
ET causes progressive functional disability affecting manual dexterity, social activities, and occupational performance. Greater tremor amplitude strongly predicts ADL impairment (r = 0.761) and reduced QoL (ortegarobles2025tremorclinicalframeworks pages 12-13). Common comorbidities include pain disorders (65–70%), hypertension (44–65%), and hyperlipidemia (30–35%) (becktepe2025epidemiologyandtreatment pages 1-2).
The following table summarizes established and experimental treatments for essential tremor:
| Treatment | Category | Mechanism of Action | Efficacy (tremor reduction %) | Key Side Effects | Evidence Level |
|---|---|---|---|---|---|
| Propranolol | First-line | Nonselective β-adrenergic blocker; reduces peripheral and possibly central tremor oscillation/amplitude | ~50–70% tremor amplitude reduction in responders; most commonly used oral therapy (ortegarobles2025tremorclinicalframeworks pages 16-18, lin2025prevalenceofdiagnosed pages 8-10) | Bradycardia, hypotension, fatigue; contraindicated in asthma/COPD; long-term discontinuation common (ortegarobles2025tremorclinicalframeworks pages 16-18, lin2025prevalenceofdiagnosed pages 1-2) | Guideline-supported standard therapy; RCT/meta-analysis and real-world evidence (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13, lin2025prevalenceofdiagnosed pages 1-2) |
| Primidone | First-line | Barbiturate-related antiseizure drug; enhances GABAergic inhibition via phenobarbital metabolite and related effects | ~50–70% tremor amplitude reduction in responders (ortegarobles2025tremorclinicalframeworks pages 16-18) | Sedation, dizziness, nausea, ataxia; tolerability limits adherence (ortegarobles2025tremorclinicalframeworks pages 16-18, alharbi2024thepharmacologicalmanagement pages 9-9) | Guideline-supported standard therapy; RCT/meta-analysis evidence (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) |
| Topiramate | Second-line | Antiseizure drug; multimodal action including sodium channel effects and enhancement of GABAergic tone | Variable; beneficial in some RCTs, but less consistent than first-line agents (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) | Cognitive slowing, paresthesia, weight loss, fatigue | Moderate evidence from RCTs/network meta-analysis; off-label (zhang2024treatmentforessential pages 13-13) |
| Gabapentin | Second-line | Modulates α2δ calcium channel subunits; reduces excitatory neurotransmission | Variable/modest benefit in some trials; inconsistent overall (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) | Somnolence, dizziness, edema, imbalance | Moderate-to-low evidence; off-label, mixed trial results (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) |
| Alprazolam | Second-line | Benzodiazepine; positive allosteric modulator of GABA-A receptors | Variable symptomatic benefit in some patients (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) | Sedation, dependence, falls, cognitive impairment | Limited-to-moderate evidence; off-label, usually adjunctive (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) |
| Botulinum toxin / incobotulinumtoxinA | Second-line / Focal refractory | Presynaptic blockade of acetylcholine release at neuromuscular junction; weakens tremulous muscles | Helpful particularly for hand, head, or voice tremor; magnitude varies by target muscle and study (zhang2024treatmentforessential pages 13-13, alharbi2024thepharmacologicalmanagement pages 9-9) | Focal weakness, dysphagia/voice weakness depending on injection site | Moderate evidence from controlled studies; useful in selected refractory cases (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) |
| Deep brain stimulation (VIM-DBS) | Surgical | High-frequency modulation of ventral intermediate thalamic nucleus within cerebello-thalamo-cortical circuit | Unilateral: ~53.4–62.8% at 12 months; bilateral: ~66–78% with better axial/voice tremor control (camargo2025thecerebellarinvolvement pages 7-8) | Dysarthria, gait imbalance, paresthesia, hardware/infection risks, stimulation-related adverse effects | High evidence for medication-refractory ET; established neurosurgical standard (ortegarobles2025tremorclinicalframeworks pages 16-18, camargo2025thecerebellarinvolvement pages 7-8) |
| MRI-guided focused ultrasound thalamotomy (MRgFUS) | Surgical | Incisionless thermal lesioning of VIM thalamus | In bilateral staged series, ~59.98% reduction in CRST A+B at 6 months after second procedure; marked QoL improvement (camargo2025thecerebellarinvolvement pages 7-8) | Gait instability, paresthesia, imbalance; usually mild-to-moderate in recent series (camargo2025thecerebellarinvolvement pages 7-8) | High/moderate evidence; established option for medication-refractory ET (ortegarobles2025tremorclinicalframeworks pages 16-18, camargo2025thecerebellarinvolvement pages 7-8) |
| Gamma Knife thalamotomy | Surgical / Experimental | Radiosurgical lesioning of contralateral VIM thalamus | Efficacy under active study; bilateral trial uses QUEST change at 12 months as primary endpoint (NCT04748640 chunk 1) | Numbness, dysgeusia, gait/speech adverse effects under surveillance (NCT04748640 chunk 1) | Ongoing Phase II/III prospective trial (NCT04748640) (NCT04748640 chunk 1) |
| SAGE-324 / BIIB124 | Experimental | Neuroactive steroid positive allosteric modulator of GABA-A receptors | Phase 2 study in 67 patients reported significant tremor reduction (camargo2025thecerebellarinvolvement pages 7-8) | Notable adverse effects; dose reductions required in 62% of participants (camargo2025thecerebellarinvolvement pages 7-8) | Mid-stage clinical evidence; experimental (camargo2025thecerebellarinvolvement pages 7-8) |
| BP1.4979 | Experimental | Selective dopamine D3 partial agonist | Efficacy unknown; current trial assesses change in TETRAS-P after 4 weeks (NCT07074002 chunk 1) | Safety/tolerability under study; no definitive profile yet in ET (NCT07074002 chunk 1) | Recruiting Phase II randomized placebo-controlled trial, NCT07074002 (NCT07074002 chunk 1) |
| AGN-151607-DP (gemibotulinumtoxinA) | Experimental | Intramuscular botulinum toxin type A formulation for upper-limb tremor | Efficacy unknown; trial measures change from baseline in TETRAS/TETRAS-UL over 72 weeks (NCT07673107 chunk 1) | Botulinum toxin-related weakness and injection-related adverse events are key concerns; safety endpoint included (NCT07673107 chunk 1) | Recruiting Phase IIb randomized placebo-controlled trial, NCT07673107 (NCT07673107 chunk 1) |
| Transcutaneous afferent patterned stimulation (TAPS) | Experimental / Device-based | Peripheral nerve stimulation intended to modulate tremor networks through patterned afferent input | Promising symptomatic tremor reduction with minimal side effects; exact effect size varies by study (ortegarobles2025tremorclinicalframeworks pages 16-18, alharbi2024thepharmacologicalmanagement pages 9-9) | Skin irritation/discomfort, variable response | Regulatory-cleared device approach with emerging clinical evidence (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13) |
| α6-GABAA modulators | Experimental / Preclinical | Positive modulation of cerebellar α6-containing extrasynaptic GABA-A receptors, especially on granule cells | Strong anti-tremor effects in harmaline models; human efficacy not yet established (handforth2023searchfornovel pages 1-2, kuo2023gabaareceptorsubtype pages 1-2) | Preclinical focus on improved tolerability versus nonselective GABAergic drugs; human AE profile unknown | Preclinical animal-model evidence; mechanistically compelling but not established clinically (handforth2023searchfornovel pages 1-2, kuo2023gabaareceptorsubtype pages 1-2, castonguay2022transcriptomiceffectsof pages 1-2) |
Table: This table summarizes established, surgical, and investigational therapies for essential tremor, including mechanisms, approximate efficacy where reported, adverse effects, and current evidence level. It is useful for comparing standard-of-care options with newer agents and device-based interventions in development.
First-line: Propranolol (the only FDA-approved medication for ET) and primidone are the standard treatments, each reducing tremor amplitude by approximately 50–70% in responders (ortegarobles2025tremorclinicalframeworks pages 16-18, lin2025prevalenceofdiagnosed pages 1-2). However, long-term adherence is limited by side effects and declining efficacy. In Germany, approximately 60% of diagnosed patients receive pharmacotherapy, with propranolol prescribed in 44–50% of treated patients (becktepe2025epidemiologyandtreatment pages 1-2). Medication discontinuation rates range from 10–70%, with 72–75% discontinuing first therapy within 12 months (becktepe2025epidemiologyandtreatment pages 1-2).
Second-line: Topiramate, gabapentin, alprazolam, and botulinum toxin injections for refractory head or voice tremor (ortegarobles2025tremorclinicalframeworks pages 16-18, zhang2024treatmentforessential pages 13-13).
Deep brain stimulation (DBS) of the VIM thalamic nucleus achieves tremor reduction of 53.4–62.8% after 12 months unilaterally, and 66–78% bilaterally with better axial and voice tremor control (camargo2025thecerebellarinvolvement pages 7-8). MRI-guided focused ultrasound (MRgFUS) thalamotomy offers a non-invasive alternative; bilateral staged procedures achieved ~60% reduction in CRST A+B score with marked QoL improvement (camargo2025thecerebellarinvolvement pages 7-8). Peripheral nerve stimulation via transcutaneous afferent patterned stimulation (TAPS) has received regulatory approval (ortegarobles2025tremorclinicalframeworks pages 16-18).
No established primary prevention strategies exist for ET. Avoiding known environmental triggers such as β-carboline exposure (harmane) may theoretically reduce risk.
The 2018 consensus criteria provide a framework for early clinical identification. However, up to 92.8% of affected individuals remain undiagnosed, indicating a critical need for improved screening (ortegarobles2025tremorclinicalframeworks pages 13-15).
Management focuses on preventing functional decline through early pharmacotherapy, occupational therapy, and adaptive devices. Monitoring for ET-to-PD conversion is recommended given the 4–5-fold increased risk (louis2025theassociationbetween pages 4-5).
Genetic counseling may be appropriate for families with strong ET history, although the polygenic nature limits predictive testing utility. The SNP-based heritability of ~24% and presence of identified risk loci could eventually support polygenic risk score applications (ogonowski2025genomewidemetaanalysisidentifies pages 1-3).
ET is uniquely human in its full clinical presentation, though natural tremor phenotypes occur in other species. The gene TENM4, strongly associated with ET, has orthologs across vertebrates, suggesting conserved axon guidance and myelination functions relevant to tremor mechanisms (cao2023associationanalysisof pages 7-8). The Grid2 gene involved in the murine ET model (Grid2dupE3 mice) shows evolutionary conservation of climbing fiber-Purkinje cell synaptic biology (pan2025targetingthefundamentals pages 2-4).
The most widely used ET model involves systemic injection of harmaline (20–40 mg/kg) in C57BL/6J mice or Wistar rats, inducing 9–16 Hz action tremor through synchronized inferior olivary neuron firing that entrains Purkinje cell complex spike activity (pan2026circuitrydynamicsof pages 16-19, kuo2023gabaareceptorsubtype pages 1-2, kosmowska2023gabaaalpha23 pages 2-3, woodward2022cerebellothalamocorticalnetworkdynamics pages 1-2). This model demonstrates excellent predictive validity, as ethanol, benzodiazepines, primidone, and GABA-A receptor potentiators that reduce human tremor also suppress harmaline tremor (kosmowska2023gabaaalpha23 pages 2-3).
This genetic model features GluRδ2 loss and climbing fiber overgrowth, producing ET-like tremor with distinct neurodynamics — global Purkinje cell hypersynchrony and resistance to propranolol and inferior olive-targeted therapies (pan2026circuitrydynamicsof pages 16-19, pan2025targetingthefundamentals pages 2-4). This model represents a cerebellar pathology-driven ET subtype, contrasting with the harmaline model.
Fecal microbiota transplantation from ET patients into germ-free mice extended tremor duration and impaired mobility, establishing causal links between gut dysbiosis and ET phenotype (zhong2023supplementationwithhighgabaproducing pages 5-7, zhong2023supplementationwithhighgabaproducing pages 2-4).
Both harmaline and genetic models capture only subsets of ET pathophysiology. The harmaline model is acute and involves a specific pharmacological mechanism, while the Grid2dupE3 model captures climbing fiber overgrowth but not the full etiological heterogeneity of human ET (pan2026circuitrydynamicsof pages 16-19, kosmowska2023gabaaalpha23 pages 2-3).
Essential tremor is a prevalent, genetically complex neurological disorder with a rapidly expanding understanding of its molecular and cellular underpinnings. Recent GWAS meta-analyses have identified up to 50 risk loci explaining ~24% SNP heritability, implicating genes involved in calcium signaling (CACNA1A, CALN1), neurotransmitter release (CPLX1), carbonic anhydrase biology (CA3), oligodendrocyte biology (BACE2), and axon guidance (TENM4) (skuladottir2024gwasmetaanalysisreveals pages 1-2, ogonowski2025genomewidemetaanalysisidentifies pages 3-5, castonguay2024asinglecelleqtl pages 1-5). The pathophysiology centers on cerebello-thalamo-cortical circuit dysfunction driven by Purkinje cell pathology, GABAergic dysregulation, and newly recognized oligodendrocyte vulnerability (ortegarobles2025tremorclinicalframeworks pages 13-15, camargo2025thecerebellarinvolvement pages 2-4, castonguay2024asinglecelleqtl pages 1-5). While propranolol and primidone remain first-line treatments with ~50–70% tremor reduction, they are limited by side effects and waning efficacy, creating significant unmet need for novel therapeutics targeting α6-GABAA receptors, dopamine D3 pathways, and neuroactive steroids (ortegarobles2025tremorclinicalframeworks pages 16-18, handforth2023searchfornovel pages 1-2, NCT07074002 chunk 1). Surgical options including DBS and focused ultrasound thalamotomy offer effective intervention for refractory cases (camargo2025thecerebellarinvolvement pages 7-8). The emerging role of the gut microbiome in ET pathogenesis through GABA-producing bacteria represents a potentially transformative therapeutic avenue (zhong2023supplementationwithhighgabaproducing pages 7-14, zhong2023supplementationwithhighgabaproducing pages 1-2).
References
(ortegarobles2025tremorclinicalframeworks pages 13-15): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(ortegarobles2025tremorclinicalframeworks pages 2-4): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(buyukserbetci2025clinicalandgenetic pages 1-2): Gulseren Buyukserbetci, Hilmi Bolat, Ummu Serpil Sari, Gizem Turan, Ayla Solmaz Avcikurt, and Figen Esmeli. Clinical and genetic characteristics of patients with essential tremor who develop parkinson’s disease. Medicina, 61:1184, Jun 2025. URL: https://doi.org/10.3390/medicina61071184, doi:10.3390/medicina61071184. This article has 0 citations.
(OpenTargets Search: Essential Tremor): Open Targets Query (Essential Tremor, 14 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(kuhlenbaumer2014geneticsofessential pages 1-3): Gregor Kuhlenbäumer, Franziska Hopfner, and Günther Deuschl. Genetics of essential tremor. Neurology, 82(11):1000-1007, Mar 2022. URL: https://doi.org/10.1212/wnl.0000000000000211, doi:10.1212/wnl.0000000000000211. This article has 65 citations and is from a highest quality peer-reviewed journal.
(skuladottir2024gwasmetaanalysisreveals pages 1-2): Astros Th. Skuladottir, Lilja Stefansdottir, Gisli H. Halldorsson, Olafur A. Stefansson, Anna Bjornsdottir, Palmi Jonsson, Vala Palmadottir, Thorgeir E. Thorgeirsson, G. Bragi Walters, Rosa S. Gisladottir, Gyda Bjornsdottir, Gudrun A. Jonsdottir, Patrick Sulem, Daniel F. Gudbjartsson, Kirk U. Knowlton, David A. Jones, Aigar Ottas, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Ole B. Pedersen, Maria Didriksen, Søren Brunak, Karina Banasik, Thomas Folkmann Hansen, Christian Erikstrup, Jakob Bay, Jens Kjærgaard Boldsen, Thorsten Brodersen, Kristoffer Burgdorf, Mona Ameri Chalmer, Khoa Manh Dinh, Joseph Dowsett, Bjarke Feenstra, Frank Geller, Daniel Gudbjartsson, Lotte Hindhede, Henrik Hjalgrim, Rikke Louise Jacobsen, Gregor Jemec, Bitten Aagaard Jensen, Katrine Kaspersen, Bertram Dalskov Kjerulff, Lisette Kogelman, Margit Anita Hørup Larsen, Ioannis Louloudis, Agnete Lundgaard, Susan Mikkelsen, Christina Mikkelsen, Ioanna Nissen, Mette Nyegaard, Ole Birger Pedersen, Alexander Pil Henriksen, Palle Duun Rohde, Klaus Rostgaard, Michael Schwinn, Hreinn Stefánsson, Erik Sørensen, Unnur Þorsteinsdóttir, Lise Wegner Thørner, Mie Topholm Bruun, Henrik Ullum, Thomas Werge, David Westergaard, Jan Haavik, Ole A. Andreassen, David Rye, Jannicke Igland, Sisse Rye Ostrowski, Lili A. Milani, Lincoln D. Nadauld, Hreinn Stefansson, and Kari Stefansson. Gwas meta-analysis reveals key risk loci in essential tremor pathogenesis. Communications Biology, Apr 2024. URL: https://doi.org/10.1038/s42003-024-06207-4, doi:10.1038/s42003-024-06207-4. This article has 18 citations and is from a peer-reviewed journal.
(skuladottir2024gwasmetaanalysisreveals pages 2-4): Astros Th. Skuladottir, Lilja Stefansdottir, Gisli H. Halldorsson, Olafur A. Stefansson, Anna Bjornsdottir, Palmi Jonsson, Vala Palmadottir, Thorgeir E. Thorgeirsson, G. Bragi Walters, Rosa S. Gisladottir, Gyda Bjornsdottir, Gudrun A. Jonsdottir, Patrick Sulem, Daniel F. Gudbjartsson, Kirk U. Knowlton, David A. Jones, Aigar Ottas, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Ole B. Pedersen, Maria Didriksen, Søren Brunak, Karina Banasik, Thomas Folkmann Hansen, Christian Erikstrup, Jakob Bay, Jens Kjærgaard Boldsen, Thorsten Brodersen, Kristoffer Burgdorf, Mona Ameri Chalmer, Khoa Manh Dinh, Joseph Dowsett, Bjarke Feenstra, Frank Geller, Daniel Gudbjartsson, Lotte Hindhede, Henrik Hjalgrim, Rikke Louise Jacobsen, Gregor Jemec, Bitten Aagaard Jensen, Katrine Kaspersen, Bertram Dalskov Kjerulff, Lisette Kogelman, Margit Anita Hørup Larsen, Ioannis Louloudis, Agnete Lundgaard, Susan Mikkelsen, Christina Mikkelsen, Ioanna Nissen, Mette Nyegaard, Ole Birger Pedersen, Alexander Pil Henriksen, Palle Duun Rohde, Klaus Rostgaard, Michael Schwinn, Hreinn Stefánsson, Erik Sørensen, Unnur Þorsteinsdóttir, Lise Wegner Thørner, Mie Topholm Bruun, Henrik Ullum, Thomas Werge, David Westergaard, Jan Haavik, Ole A. Andreassen, David Rye, Jannicke Igland, Sisse Rye Ostrowski, Lili A. Milani, Lincoln D. Nadauld, Hreinn Stefansson, and Kari Stefansson. Gwas meta-analysis reveals key risk loci in essential tremor pathogenesis. Communications Biology, Apr 2024. URL: https://doi.org/10.1038/s42003-024-06207-4, doi:10.1038/s42003-024-06207-4. This article has 18 citations and is from a peer-reviewed journal.
(ogonowski2025genomewidemetaanalysisidentifies pages 3-5): Natalia S. Ogonowski, Fangyuan Cao, Victor Flores-Ocampo, Sofia Salazar-Magaña, Mathias Seviiri, Liyang Song, Sam Nayler, Jason Kugelman, Gabriel Cuellar-Partida, Stuart MacGregor, Hae Kyung Im, Ian H. Harding, Puya Gharahkhani, Nicholas G. Martin, Kishore R. Kumar, Jian Yang, Santiago Diaz-Torres, and Miguel E. Rentería. Genome-wide meta-analysis identifies 47 novel loci and links essential tremor to ventral diencephalon and cerebellum morphometry. MedRxiv, Nov 2025. URL: https://doi.org/10.1101/2025.11.10.25339873, doi:10.1101/2025.11.10.25339873. This article has 0 citations.
(ogonowski2025genomewidemetaanalysisidentifies pages 7-9): Natalia S. Ogonowski, Fangyuan Cao, Victor Flores-Ocampo, Sofia Salazar-Magaña, Mathias Seviiri, Liyang Song, Sam Nayler, Jason Kugelman, Gabriel Cuellar-Partida, Stuart MacGregor, Hae Kyung Im, Ian H. Harding, Puya Gharahkhani, Nicholas G. Martin, Kishore R. Kumar, Jian Yang, Santiago Diaz-Torres, and Miguel E. Rentería. Genome-wide meta-analysis identifies 47 novel loci and links essential tremor to ventral diencephalon and cerebellum morphometry. MedRxiv, Nov 2025. URL: https://doi.org/10.1101/2025.11.10.25339873, doi:10.1101/2025.11.10.25339873. This article has 0 citations.
(ogonowski2025genomewidemetaanalysisidentifies pages 1-3): Natalia S. Ogonowski, Fangyuan Cao, Victor Flores-Ocampo, Sofia Salazar-Magaña, Mathias Seviiri, Liyang Song, Sam Nayler, Jason Kugelman, Gabriel Cuellar-Partida, Stuart MacGregor, Hae Kyung Im, Ian H. Harding, Puya Gharahkhani, Nicholas G. Martin, Kishore R. Kumar, Jian Yang, Santiago Diaz-Torres, and Miguel E. Rentería. Genome-wide meta-analysis identifies 47 novel loci and links essential tremor to ventral diencephalon and cerebellum morphometry. MedRxiv, Nov 2025. URL: https://doi.org/10.1101/2025.11.10.25339873, doi:10.1101/2025.11.10.25339873. This article has 0 citations.
(kuhlenbaumer2014geneticsofessential pages 4-6): Gregor Kuhlenbäumer, Franziska Hopfner, and Günther Deuschl. Genetics of essential tremor. Neurology, 82(11):1000-1007, Mar 2022. URL: https://doi.org/10.1212/wnl.0000000000000211, doi:10.1212/wnl.0000000000000211. This article has 65 citations and is from a highest quality peer-reviewed journal.
(cao2023associationanalysisof pages 7-8): Lanxiao Cao, Luyan Gu, Jiali Pu, Dayao Lv, Jun Tian, Xinzhen Yin, Ting Gao, Zhe Song, Jinyu Lu, Gaohua Zhao, Baorong Zhang, Yaping Yan, and Guohua Zhao. Association analysis of 27 single nucleotide polymorphisms in a chinese population with essential tremor. Journal of Molecular Neuroscience, 73:205-213, Mar 2023. URL: https://doi.org/10.1007/s12031-023-02106-1, doi:10.1007/s12031-023-02106-1. This article has 2 citations and is from a peer-reviewed journal.
(kosmowska2023gabaaalpha23 pages 2-3): Barbara Kosmowska, Martyna Paleczna, Dominika Biała, Justyna Kadłuczka, Jadwiga Wardas, Jeffrey M. Witkin, James M. Cook, Dishary Sharmin, Monika Marcinkowska, and Katarzyna Z. Kuter. Gaba-a alpha 2/3 but not alpha 1 receptor subunit ligand inhibits harmaline and pimozide-induced tremor in rats. Biomolecules, 13:197, Jan 2023. URL: https://doi.org/10.3390/biom13020197, doi:10.3390/biom13020197. This article has 10 citations.
(handforth2023searchfornovel pages 1-2): Adrian Handforth, Ram P. Singh, Marco Treven, and Margot Ernst. Search for novel therapies for essential tremor based on positive modulation of α6-containing gabaa receptors. Tremor and Other Hyperkinetic Movements, Oct 2023. URL: https://doi.org/10.5334/tohm.796, doi:10.5334/tohm.796. This article has 10 citations and is from a peer-reviewed journal.
(kuo2023gabaareceptorsubtype pages 1-2): Sheng-Han Kuo. Gabaa receptor subtype specificity in essential tremor. Neurotherapeutics, 20:372-374, Mar 2023. URL: https://doi.org/10.1007/s13311-023-01341-z, doi:10.1007/s13311-023-01341-z. This article has 1 citations and is from a peer-reviewed journal.
(zhong2023supplementationwithhighgabaproducing pages 7-14): Hao-Jie Zhong, Si-Qi Wang, Ruo-Xin Zhang, Yu-Pei Zhuang, Longyan Li, Shuo-Zhao Yi, Ying Li, Lei Wu, Yu Ding, Jumei Zhang, Xinqiang Xie, Xing-Xiang He, and Qingping Wu. Supplementation with high-gaba-producing lactobacillus plantarum l5 ameliorates essential tremor triggered by decreased gut bacteria-derived gaba. Translational Neurodegeneration, Dec 2023. URL: https://doi.org/10.1186/s40035-023-00391-9, doi:10.1186/s40035-023-00391-9. This article has 52 citations and is from a domain leading peer-reviewed journal.
(zhong2023supplementationwithhighgabaproducing pages 1-2): Hao-Jie Zhong, Si-Qi Wang, Ruo-Xin Zhang, Yu-Pei Zhuang, Longyan Li, Shuo-Zhao Yi, Ying Li, Lei Wu, Yu Ding, Jumei Zhang, Xinqiang Xie, Xing-Xiang He, and Qingping Wu. Supplementation with high-gaba-producing lactobacillus plantarum l5 ameliorates essential tremor triggered by decreased gut bacteria-derived gaba. Translational Neurodegeneration, Dec 2023. URL: https://doi.org/10.1186/s40035-023-00391-9, doi:10.1186/s40035-023-00391-9. This article has 52 citations and is from a domain leading peer-reviewed journal.
(zhong2023supplementationwithhighgabaproducing pages 14-17): Hao-Jie Zhong, Si-Qi Wang, Ruo-Xin Zhang, Yu-Pei Zhuang, Longyan Li, Shuo-Zhao Yi, Ying Li, Lei Wu, Yu Ding, Jumei Zhang, Xinqiang Xie, Xing-Xiang He, and Qingping Wu. Supplementation with high-gaba-producing lactobacillus plantarum l5 ameliorates essential tremor triggered by decreased gut bacteria-derived gaba. Translational Neurodegeneration, Dec 2023. URL: https://doi.org/10.1186/s40035-023-00391-9, doi:10.1186/s40035-023-00391-9. This article has 52 citations and is from a domain leading peer-reviewed journal.
(ogonowski2025genomewidemetaanalysisidentifies pages 9-11): Natalia S. Ogonowski, Fangyuan Cao, Victor Flores-Ocampo, Sofia Salazar-Magaña, Mathias Seviiri, Liyang Song, Sam Nayler, Jason Kugelman, Gabriel Cuellar-Partida, Stuart MacGregor, Hae Kyung Im, Ian H. Harding, Puya Gharahkhani, Nicholas G. Martin, Kishore R. Kumar, Jian Yang, Santiago Diaz-Torres, and Miguel E. Rentería. Genome-wide meta-analysis identifies 47 novel loci and links essential tremor to ventral diencephalon and cerebellum morphometry. MedRxiv, Nov 2025. URL: https://doi.org/10.1101/2025.11.10.25339873, doi:10.1101/2025.11.10.25339873. This article has 0 citations.
(skuladottir2024gwasmetaanalysisreveals pages 4-4): Astros Th. Skuladottir, Lilja Stefansdottir, Gisli H. Halldorsson, Olafur A. Stefansson, Anna Bjornsdottir, Palmi Jonsson, Vala Palmadottir, Thorgeir E. Thorgeirsson, G. Bragi Walters, Rosa S. Gisladottir, Gyda Bjornsdottir, Gudrun A. Jonsdottir, Patrick Sulem, Daniel F. Gudbjartsson, Kirk U. Knowlton, David A. Jones, Aigar Ottas, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Ole B. Pedersen, Maria Didriksen, Søren Brunak, Karina Banasik, Thomas Folkmann Hansen, Christian Erikstrup, Jakob Bay, Jens Kjærgaard Boldsen, Thorsten Brodersen, Kristoffer Burgdorf, Mona Ameri Chalmer, Khoa Manh Dinh, Joseph Dowsett, Bjarke Feenstra, Frank Geller, Daniel Gudbjartsson, Lotte Hindhede, Henrik Hjalgrim, Rikke Louise Jacobsen, Gregor Jemec, Bitten Aagaard Jensen, Katrine Kaspersen, Bertram Dalskov Kjerulff, Lisette Kogelman, Margit Anita Hørup Larsen, Ioannis Louloudis, Agnete Lundgaard, Susan Mikkelsen, Christina Mikkelsen, Ioanna Nissen, Mette Nyegaard, Ole Birger Pedersen, Alexander Pil Henriksen, Palle Duun Rohde, Klaus Rostgaard, Michael Schwinn, Hreinn Stefánsson, Erik Sørensen, Unnur Þorsteinsdóttir, Lise Wegner Thørner, Mie Topholm Bruun, Henrik Ullum, Thomas Werge, David Westergaard, Jan Haavik, Ole A. Andreassen, David Rye, Jannicke Igland, Sisse Rye Ostrowski, Lili A. Milani, Lincoln D. Nadauld, Hreinn Stefansson, and Kari Stefansson. Gwas meta-analysis reveals key risk loci in essential tremor pathogenesis. Communications Biology, Apr 2024. URL: https://doi.org/10.1038/s42003-024-06207-4, doi:10.1038/s42003-024-06207-4. This article has 18 citations and is from a peer-reviewed journal.
(castonguay2024asinglecelleqtl pages 1-5): Charles-Etienne Castonguay, Farah Aboasali, Miranda Medeiros, Théodore Becret, Zoe Schmilovich, Anouar Khayachi, Alex Rajput, Patrick A. Dion, and Guy A Rouleau. A single-cell eqtl atlas of the human cerebellum reveals vulnerability of oligodendrocytes in essential tremor. bioRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.22.595233, doi:10.1101/2024.05.22.595233. This article has 6 citations.
(zeng2024associationanalysisof pages 8-9): Sheng Zeng, Xun Zhou, Runcheng He, Yuwen Zhao, Zhenhua Liu, Qian Xu, Jifeng Guo, Xinxiang Yan, Jinchen Li, Beisha Tang, and Qiying Sun. Association analysis of essential tremor-associated genetic variants in sporadic late-onset parkinson’s disease. Tremor and Other Hyperkinetic Movements, May 2024. URL: https://doi.org/10.5334/tohm.885, doi:10.5334/tohm.885. This article has 2 citations and is from a peer-reviewed journal.
(ortegarobles2025tremorclinicalframeworks pages 15-16): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(erro2023diagnosisversusclassification pages 2-3): Roberto Erro, Marina Picillo, Maria Teresa Pellecchia, and Paolo Barone. Diagnosis versus classification of essential tremor: a research perspective. Journal of Movement Disorders, 16:152-157, May 2023. URL: https://doi.org/10.14802/jmd.23020, doi:10.14802/jmd.23020. This article has 7 citations and is from a peer-reviewed journal.
(ortegarobles2025tremorclinicalframeworks pages 10-12): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(ortegarobles2025tremorclinicalframeworks pages 12-13): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(martuscello2023geneexpressionanalysis pages 9-11): Regina T. Martuscello, Karthigayini Sivaprakasam, Whitney Hartstone, Sheng-Han Kuo, Genevieve Konopka, Elan D. Louis, and Phyllis L. Faust. Gene expression analysis of laser-captured purkinje cells in the essential tremor cerebellum. The Cerebellum, 22:1166-1181, Oct 2023. URL: https://doi.org/10.1007/s12311-022-01483-4, doi:10.1007/s12311-022-01483-4. This article has 13 citations.
(zhong2023supplementationwithhighgabaproducing pages 5-7): Hao-Jie Zhong, Si-Qi Wang, Ruo-Xin Zhang, Yu-Pei Zhuang, Longyan Li, Shuo-Zhao Yi, Ying Li, Lei Wu, Yu Ding, Jumei Zhang, Xinqiang Xie, Xing-Xiang He, and Qingping Wu. Supplementation with high-gaba-producing lactobacillus plantarum l5 ameliorates essential tremor triggered by decreased gut bacteria-derived gaba. Translational Neurodegeneration, Dec 2023. URL: https://doi.org/10.1186/s40035-023-00391-9, doi:10.1186/s40035-023-00391-9. This article has 52 citations and is from a domain leading peer-reviewed journal.
(ortegarobles2025tremorclinicalframeworks pages 6-8): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(camargo2025thecerebellarinvolvement pages 2-4): Carlos Henrique Ferreira Camargo, Léo Coutinho, Luis Eduardo Borges de Macedo Zubko, G. Franklin, and Hélio Afonso Ghizoni Teive. The cerebellar involvement in essential tremor: the connecting roads. Arquivos de Neuro-Psiquiatria, 83:001-012, Oct 2025. URL: https://doi.org/10.1055/s-0045-1812324, doi:10.1055/s-0045-1812324. This article has 0 citations and is from a peer-reviewed journal.
(camargo2025thecerebellarinvolvement pages 1-2): Carlos Henrique Ferreira Camargo, Léo Coutinho, Luis Eduardo Borges de Macedo Zubko, G. Franklin, and Hélio Afonso Ghizoni Teive. The cerebellar involvement in essential tremor: the connecting roads. Arquivos de Neuro-Psiquiatria, 83:001-012, Oct 2025. URL: https://doi.org/10.1055/s-0045-1812324, doi:10.1055/s-0045-1812324. This article has 0 citations and is from a peer-reviewed journal.
(martuscello2023geneexpressionanalysis pages 12-14): Regina T. Martuscello, Karthigayini Sivaprakasam, Whitney Hartstone, Sheng-Han Kuo, Genevieve Konopka, Elan D. Louis, and Phyllis L. Faust. Gene expression analysis of laser-captured purkinje cells in the essential tremor cerebellum. The Cerebellum, 22:1166-1181, Oct 2023. URL: https://doi.org/10.1007/s12311-022-01483-4, doi:10.1007/s12311-022-01483-4. This article has 13 citations.
(martuscello2023geneexpressionanalysis pages 6-7): Regina T. Martuscello, Karthigayini Sivaprakasam, Whitney Hartstone, Sheng-Han Kuo, Genevieve Konopka, Elan D. Louis, and Phyllis L. Faust. Gene expression analysis of laser-captured purkinje cells in the essential tremor cerebellum. The Cerebellum, 22:1166-1181, Oct 2023. URL: https://doi.org/10.1007/s12311-022-01483-4, doi:10.1007/s12311-022-01483-4. This article has 13 citations.
(kosmowska2023gabaaalpha23 pages 16-17): Barbara Kosmowska, Martyna Paleczna, Dominika Biała, Justyna Kadłuczka, Jadwiga Wardas, Jeffrey M. Witkin, James M. Cook, Dishary Sharmin, Monika Marcinkowska, and Katarzyna Z. Kuter. Gaba-a alpha 2/3 but not alpha 1 receptor subunit ligand inhibits harmaline and pimozide-induced tremor in rats. Biomolecules, 13:197, Jan 2023. URL: https://doi.org/10.3390/biom13020197, doi:10.3390/biom13020197. This article has 10 citations.
(pan2026circuitrydynamicsof pages 32-34): Ming-Kai Pan, Liang-Ying Chen, Yi-Mei Wang, Alexander White, Jou-Yu Ho, Shun-Ying Chen, Yi-Fan Chen, Ting-Yu Liang, Liang-Yin Lu, Ting-Yi Kuo, Wen-Chuan Liu, Jye-Chang Lee, David Friel, Peter Thomas, Shusen Pu, Sheng-Han Kuo, Shi-Wei Chu, Shun-Chi Wu, Chung-Chuan Lo, and George Ermentrout. Circuitry dynamics of the cerebellum inform differential therapeutic responses and patient stratification in essential tremor. Unknown journal, Feb 2026. URL: https://doi.org/10.21203/rs.3.rs-8705665/v1, doi:10.21203/rs.3.rs-8705665/v1.
(gironell2022isessentialtremor pages 1-2): Alexandre Gironell. Is essential tremor a disorder of primary gaba dysfunction? yes. International review of neurobiology, 163:259-284, Jan 2022. URL: https://doi.org/10.1016/bs.irn.2022.02.005, doi:10.1016/bs.irn.2022.02.005. This article has 13 citations and is from a peer-reviewed journal.
(woodward2022cerebellothalamocorticalnetworkdynamics pages 1-2): Kathryn Woodward, Richard Apps, Marc Goodfellow, and Nadia L. Cerminara. Cerebello-thalamo-cortical network dynamics in the harmaline rodent model of essential tremor. Frontiers in Systems Neuroscience, Jul 2022. URL: https://doi.org/10.3389/fnsys.2022.899446, doi:10.3389/fnsys.2022.899446. This article has 8 citations and is from a peer-reviewed journal.
(castonguay2024asinglecelleqtl pages 45-47): Charles-Etienne Castonguay, Farah Aboasali, Miranda Medeiros, Théodore Becret, Zoe Schmilovich, Anouar Khayachi, Alex Rajput, Patrick A. Dion, and Guy A Rouleau. A single-cell eqtl atlas of the human cerebellum reveals vulnerability of oligodendrocytes in essential tremor. bioRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.22.595233, doi:10.1101/2024.05.22.595233. This article has 6 citations.
(castonguay2022transcriptomiceffectsof pages 3-4): Charles-Etienne Castonguay, Calwing Liao, Anouar Khayachi, Yumin Liu, Miranda Medeiros, Gabrielle Houle, Jay P. Ross, Patrick A. Dion, and Guy A. Rouleau. Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor. npj Genomic Medicine, Aug 2022. URL: https://doi.org/10.1038/s41525-022-00318-9, doi:10.1038/s41525-022-00318-9. This article has 13 citations and is from a peer-reviewed journal.
(castonguay2022transcriptomiceffectsof pages 1-2): Charles-Etienne Castonguay, Calwing Liao, Anouar Khayachi, Yumin Liu, Miranda Medeiros, Gabrielle Houle, Jay P. Ross, Patrick A. Dion, and Guy A. Rouleau. Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor. npj Genomic Medicine, Aug 2022. URL: https://doi.org/10.1038/s41525-022-00318-9, doi:10.1038/s41525-022-00318-9. This article has 13 citations and is from a peer-reviewed journal.
(camargo2025thecerebellarinvolvement pages 7-8): Carlos Henrique Ferreira Camargo, Léo Coutinho, Luis Eduardo Borges de Macedo Zubko, G. Franklin, and Hélio Afonso Ghizoni Teive. The cerebellar involvement in essential tremor: the connecting roads. Arquivos de Neuro-Psiquiatria, 83:001-012, Oct 2025. URL: https://doi.org/10.1055/s-0045-1812324, doi:10.1055/s-0045-1812324. This article has 0 citations and is from a peer-reviewed journal.
(castonguay2024asinglecelleqtl pages 31-33): Charles-Etienne Castonguay, Farah Aboasali, Miranda Medeiros, Théodore Becret, Zoe Schmilovich, Anouar Khayachi, Alex Rajput, Patrick A. Dion, and Guy A Rouleau. A single-cell eqtl atlas of the human cerebellum reveals vulnerability of oligodendrocytes in essential tremor. bioRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.22.595233, doi:10.1101/2024.05.22.595233. This article has 6 citations.
(louis2023conversionrateof pages 4-5): Elan D. Louis, Diane Berry, Ali Ghanem, and Stephanie A. Cosentino. Conversion rate of essential tremor to essential tremor parkinson disease. Neurology Clinical Practice, Jun 2023. URL: https://doi.org/10.1212/cpj.0000000000200162, doi:10.1212/cpj.0000000000200162. This article has 33 citations.
(louis2023conversionrateof pages 1-2): Elan D. Louis, Diane Berry, Ali Ghanem, and Stephanie A. Cosentino. Conversion rate of essential tremor to essential tremor parkinson disease. Neurology Clinical Practice, Jun 2023. URL: https://doi.org/10.1212/cpj.0000000000200162, doi:10.1212/cpj.0000000000200162. This article has 33 citations.
(louis2025theassociationbetween pages 4-5): Elan D. Louis. The association between essential tremor and parkinson’s disease: a systematic review of clinical and epidemiological studies. Journal of Clinical Medicine, 14:2637, Apr 2025. URL: https://doi.org/10.3390/jcm14082637, doi:10.3390/jcm14082637. This article has 15 citations.
(lin2025prevalenceofdiagnosed pages 1-2): Junji Lin, Rajesh Pahwa, Elan D. Louis, Ragy Saad, Kelly E. Lyons, Michael Markowitz, Liza R. Gibbs, Aisara Chansakul, John Kroner, Douglas S. Fuller, Weiyi Ni, Arthur Sillah, Michelle Baladi, Luigi M. Barbato, and Sanket Shah. Prevalence of diagnosed essential tremor in the united states: an administrative claims-based study. Tremor and Other Hyperkinetic Movements, 15:51, Oct 2025. URL: https://doi.org/10.5334/tohm.1060, doi:10.5334/tohm.1060. This article has 1 citations and is from a peer-reviewed journal.
(lin2025prevalenceofdiagnosed pages 8-10): Junji Lin, Rajesh Pahwa, Elan D. Louis, Ragy Saad, Kelly E. Lyons, Michael Markowitz, Liza R. Gibbs, Aisara Chansakul, John Kroner, Douglas S. Fuller, Weiyi Ni, Arthur Sillah, Michelle Baladi, Luigi M. Barbato, and Sanket Shah. Prevalence of diagnosed essential tremor in the united states: an administrative claims-based study. Tremor and Other Hyperkinetic Movements, 15:51, Oct 2025. URL: https://doi.org/10.5334/tohm.1060, doi:10.5334/tohm.1060. This article has 1 citations and is from a peer-reviewed journal.
(becktepe2025epidemiologyandtreatment pages 1-2): Jos S. Becktepe, Keltie McDonald, Sabrina Müller, Thomas Wilke, Evi Zhuleku, Karen Appiah, Natasha Dzimitrowicz, Jade Marshall, Javier Sabater, Luigi M. Barbato, and Tabish A. Saifee. Epidemiology and treatment patterns of essential tremor: a retrospective cohort analysis in germany. Frontiers in Neurology, Jul 2025. URL: https://doi.org/10.3389/fneur.2025.1580919, doi:10.3389/fneur.2025.1580919. This article has 4 citations and is from a peer-reviewed journal.
(NCT04748640 chunk 1): Christian Iorio-Morin. Bilateral Essential Tremor Treatment With Gamma Knife. Université de Sherbrooke. 2021. ClinicalTrials.gov Identifier: NCT04748640
(ortegarobles2025tremorclinicalframeworks pages 16-18): Emmanuel Ortega-Robles and Oscar Arias-Carrión. Tremor: clinical frameworks, network dysfunction and therapeutics. Brain Sciences, 15:799, Jul 2025. URL: https://doi.org/10.3390/brainsci15080799, doi:10.3390/brainsci15080799. This article has 9 citations.
(zhang2024treatmentforessential pages 13-13): Junjiao Zhang, Rui Yan, Yu-Ling Cui, Dongning Su, and Tao Feng. Treatment for essential tremor: a systematic review and bayesian model-based network meta-analysis of rcts. eClinicalMedicine, Oct 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102889, doi:10.1016/j.eclinm.2024.102889. This article has 14 citations and is from a peer-reviewed journal.
(alharbi2024thepharmacologicalmanagement pages 9-9): Oqab Alharbi, Sofian A Albaibi, Abdullah A Almutairi, Emad Alsaqabi, Meshal Alharbi, Bader S Alharbi, Mohammad F Almansour, and Zainah A Al-Qahtani. The pharmacological management of essential tremor and its long-term effects on patient quality of life: a systematic review. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.76016, doi:10.7759/cureus.76016. This article has 7 citations.
(NCT07074002 chunk 1): Proof of Concept Study on BP1.4979 Effect on Essential Tremor. Bioprojet. 2025. ClinicalTrials.gov Identifier: NCT07074002
(NCT07673107 chunk 1): Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor. AbbVie. 2026. ClinicalTrials.gov Identifier: NCT07673107
(pan2025targetingthefundamentals pages 2-4): Ming-Kai Pan. Targeting the fundamentals for tremors: the frequency and amplitude coding in essential tremor. Journal of Biomedical Science, Feb 2025. URL: https://doi.org/10.1186/s12929-024-01112-8, doi:10.1186/s12929-024-01112-8. This article has 10 citations and is from a domain leading peer-reviewed journal.
(pan2026circuitrydynamicsof pages 16-19): Ming-Kai Pan, Liang-Ying Chen, Yi-Mei Wang, Alexander White, Jou-Yu Ho, Shun-Ying Chen, Yi-Fan Chen, Ting-Yu Liang, Liang-Yin Lu, Ting-Yi Kuo, Wen-Chuan Liu, Jye-Chang Lee, David Friel, Peter Thomas, Shusen Pu, Sheng-Han Kuo, Shi-Wei Chu, Shun-Chi Wu, Chung-Chuan Lo, and George Ermentrout. Circuitry dynamics of the cerebellum inform differential therapeutic responses and patient stratification in essential tremor. Unknown journal, Feb 2026. URL: https://doi.org/10.21203/rs.3.rs-8705665/v1, doi:10.21203/rs.3.rs-8705665/v1.
(zhong2023supplementationwithhighgabaproducing pages 2-4): Hao-Jie Zhong, Si-Qi Wang, Ruo-Xin Zhang, Yu-Pei Zhuang, Longyan Li, Shuo-Zhao Yi, Ying Li, Lei Wu, Yu Ding, Jumei Zhang, Xinqiang Xie, Xing-Xiang He, and Qingping Wu. Supplementation with high-gaba-producing lactobacillus plantarum l5 ameliorates essential tremor triggered by decreased gut bacteria-derived gaba. Translational Neurodegeneration, Dec 2023. URL: https://doi.org/10.1186/s40035-023-00391-9, doi:10.1186/s40035-023-00391-9. This article has 52 citations and is from a domain leading peer-reviewed journal.